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L’etiologie de l’hypertension implique des interactions complexes
entre les facteurs genetiques, environnementaux et physio-
pathologiques qui influencent de nombreux systèmes de regulation.
L’hypertension est typiquement associee à une dysfonction vasculaire,
à un remodelage cardiovasculaire, à une dysfonction renale et à une
stimulation du système nerveux sympathique. De nouvelles donnees
indiquent que le système immunitaire est egalement important et que
les cellules immunitaires activees migrent et s’accumulent dans les
tissus, favorisant l’inflammation, la fibrose et la lesion des organesHypertension is a complex, multifactorial, and multisystem family of nonphagocytic NADPH oxidases (Nox1, Nox2, and
disorder as originally described by Irvine Paige in his mosaic
theory when he proposed that high blood pressure involves
interplay among many elements, including genetic, environ-
mental, anatomic, adaptive, neural, endocrine, humoral, and
hemodynamic factors.1 Since then, there has been enormous
progress in discovering the molecular and cellular processes
that connect the numerous components underlying hyper-
tension. In 2013, David Harrison revisited Paige’s mosaic
theory, highlighting common molecular mechanisms, specif-
ically oxidative stress and inflammation, as major drivers
coordinating diverse cellular events and organ systems in
hypertension.2
Oxidative stress is characterized by excessive production of
reactive oxygen species (ROS) and altered oxidation-reduction
(redox) state. These molecular events induce protein oxidation
and dysregulated cell signalling, leading to inflammation,
proliferation, apoptosis, migration, and fibrosis, which are
important processes contributing to impaired vascular func-
tion, cardiovascular remodelling, renal dysfunction, immune
cell activation, and sympathetic nervous system excitation in
hypertension.1-4 A major source of cardiovascular ROS is aNox4 in rodents and Nox1, Nox2, Nox4, and Nox5 in
humans).5,6 Expression and activation of Nox isoforms are
increased in hypertension and are a likely cause of oxidative
stress in cardiovascular, renal, and immune cells in
hypertension-associated target organ damage.6-8 Other enzy-
matic sources of ROS include mitochondrial oxidases,
xanthine oxidase, endoplasmic reticular oxidases, and uncou-
pled nitric oxide synthase (NOS).
Whereas the ROS-generating role of non-NADPH oxi-
dases in cardiovascular cells seems to be minor in physiologic
conditions,9 growing evidence suggests that ROS generated in
mitochondria and the endoplasmic reticulum (ER) may
contribute to oxidative stress in hypertension.10-12 This likely
involves cross-talk between Noxs and mitochondria/ER. In
particular, the concept of ROS-induced ROS release (RIRR)
may be important, whereby ROS formed in one region acti-
vate ROS in another region13 (Fig. 1). A number of phar-
macologic strategies have been developed to lower cross-talk
between Noxs and mitochondria, which may reduce RIRR.14
Mitochondrial oxidative stresseinduced endothelial dysfunc-
tion in hypertension has been attributed to reduced sirtuin 3
(SIRT3)emediated superoxide dismutase 2 (SOD2) signal-
ling.15 These processes were ameliorated by restoration of
SIRT3, suggesting that SIRT3 influences the mitochondrial
redox state by regulating mitochondrial antioxidant systems.
Mito-Tempol, an SOD mimetic, accumulates in mitochon-
dria and has been shown to improve endothelial function,
inhibit ROS production, and reduce blood pressure in
experimental hypertension.10 Moreover, recent studies indian Cardiovascular Society. This is an open access article under the CC BY
oxidants and antioxidants in favour of the oxidants that leads to a
disruption of oxidation-reduction (redox) signalling and control and
molecular damage. Physiologically, reactive oxygen species (ROS) act
as signalling molecules and influence cell function through highly
regulated redox-sensitive signal transduction. In hypertension, oxida-
tive stress promotes posttranslational modification (oxidation and
phosphorylation) of proteins and aberrant signalling with consequent
cell and tissue damage. Many enzymatic systems generate ROS, but
NADPH oxidases (Nox) are the major sources in cells of the heart,
vessels, kidneys, and immune system. Expression and activity of Nox
are increased in hypertension and are the major systems responsible
for oxidative stress in cardiovascular disease. Here we provide a uni-
fying concept where oxidative stress is a common mediator underlying
pathophysiologic processes in hypertension. We focus on some novel
concepts whereby ROS influence vascular function, aldosterone/
mineralocorticoid actions, and immunoinflammation, all important
processes contributing to the development of hypertension.
cibles. Ces processus ont en commun le stress oxydatif, defini comme
etant un desequilibre entre les oxydants et les antioxydants en faveur
des oxydants qui conduit à une perturbation de la signalisation et du
contrôle de l’oxydoreduction (redox) et à des dommages moleculaires.
Physiologiquement, les espèces reactives de l’oxygène (ERO) agissent
comme des molecules de signalisation et influencent la fonction cel-
lulaire par une transduction du signal hautement regulee et sensible à
l’oxydoreduction. Dans l’hypertension, le stress oxydatif favorise la
modification post-traductionnelle (oxydation et phosphorylation) des
proteines et une signalisation aberrante avec des dommages con-
sequents aux cellules et aux tissus. De nombreux systèmes enzyma-
tiques genèrent des ERO, mais les NADPH oxydases (Nox) en sont les
principales sources dans les cellules du cœur, des vaisseaux, des reins
et du système immunitaire. L’expression et l’activite des Nox sont
accrues en cas d’hypertension et sont les principaux systèmes
responsables du stress oxydatif dans les maladies cardiovasculaires.
Nous presentons ici un concept unificateur dans lequel le stress oxy-
datif est un mediateur commun qui sous-tend les processus physio-
pathologiques de l’hypertension. Nous nous concentrons sur quelques
nouveaux concepts selon lesquels les ERO influencent la fonction
vasculaire, les actions de l’aldosterone et des mineralocorticoïdes, et
l’immuno-inflammation, autant de processus importants contribuant
au developpement de l’hypertension.
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Volume 36 2020humans showed that chronic supplementation with a mito-
chondrial antioxidant (MitoQ) improves vascular function in
aged individuals.16 Mitochondrial dysfunction and ROS
generation in the brain seem to be especially important in
neurogenic hypertension, where neural mitochondrial
biogenesis and bioenergetics influence sympathetic outflow to
the cardiovascular system.17
The ER has also been implicated in oxidative stress in
hypertension. We demonstrated that vascular hyper-
contractility in stroke-prone spontaneously hypertensive
rats (SHR-SPs) involves oxidative and ER stress through
Nox4-dependent processes.18 Inhibition of ER stress with
the use of 4-phenylbutyric acid (4-PBA) and STF083010
(an IRE1-XBP1 disruptor) ameliorated vascular dysfunc-
tion in SHR-SPs.18 Treatment of SHRs with 4-PBA
reduced blood pressure and improved vascular function
and structure by ameliorating ER stress.12 Although ER-
and mitochondria-derived ROS may contribute in part to
oxidative stress in hypertension, the upstream driving fac-
tor appears to be Nox activation.13,14
Oxidative stress and altered redox signalling are emerging
as major pathogenic factors in cardiovascular disease. This
review examines the role of cellular oxidants in the cardio-
vascular system and focuses on oxidative stress as a common
molecular process in some pathophysiologic events underlying
hypertension. In particular, we discuss some novel concepts
related to the central role of ROS in vascular function,
hyperaldosteronism, and inflammation in hypertension. ROS
also influence many other systems involved in hypertension,
and the reader is referred to recent papers for further details.2-8Reactive Oxygen Species, Oxidative Stress, and
Redox Signalling in Hypertension
In physiologic conditions, ROS are intimately involved in
and required for normal biological function, in large partthrough tightly controlled redox regulation, redox signaling
and redox sensing.19 In pathological conditions, uncontrolled
ROS production leads to oxidative stress defined as “an
imbalance between oxidants and antioxidants in favor of the
oxidants, leading to a disruption of redox signaling and con-
trol and/or molecular damage.”20 In the cardiovascular sys-
tem, the most important ROS are superoxide anion (O2
),
hydrogen peroxide (H2O2), nitric oxide (NO), and perox-
ynitrite (ONOO).19-21 Although O2
 is highly unstable and
cell membrane impermeable, H2O2 is cell membrane
permeable, is stable, and has a longer half-life than O2,

making it an efficient signalling molecule.22,23 NO, produced
enzymatically by NOS, is the prototype endothelial-derived
vasodilator.24,25 When NO reacts with O2,
 it forms
ONOO, a strong oxidant that is highly unstable.26 When
protonated (HOONO), peoxynitrite is cell membrane
permeable. The interplay between O2
 and NO, together
with dysregulated production of O2
 and H2O2, contributes
to altered cellular redox status and oxidative damage of cells
and tissues.27
ROS influence cell function by modifying proteins
through posttranslational modifications, such as oxidation
(sulfenylation, nitrosylation, glutathionylation, and carbomy-
lation) and phosphorylation.28-30 Proteins that are redox
sensitive include ion transporters, receptors, signalling mole-
cules, transcription factors, cytoskeletal structural proteins,
and matrix metalloproteases, all of which are involved in
regulating vascular, cardiac, and renal functions.30,31 ROS are
key signalling molecules through which vasoactive agents such
as angiotensin II (Ang II), endothelin-1 (ET-1), aldosterone,
and prostanoids mediate cellular effects, and they regulate
intracellular calcium homeostasis,32-35 which is important in
triggering and maintaining vasoconstriction and cardiac
contraction. ROS activate all 3 members of the mitogen-
activated protein kinase (MAPK) family, including ERK1/2,
p38MAPK, and JNK, which control cardiac and vascular cell
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ROS also influence tyrosine kinases important in cardiovas-
cular inflammation and fibrosis, such as c-Src, PI3K/Akt,
FAK, and receptor tyrosine kinases (VEGFR, EGFR,
PDGFR), and they are critically involved in oxidation of actin
and actin-associated proteins important in cystoskeletal
organization.38-40 ROS stimulate activation of transcription
factors (nuclear factor [NF] kB, signal transducer and acti-
vator of transcription [STAT] activator protein 1 [AP-1], and
hypoxia-inducible factor 1 [HIF-1]), proinflammatory genes,
chemokine and cytokine production, and recruitment and
activation of inflammatory and immune cells that promote
cardiovascular and renal inflammation and fibrosis,41-43 which
are important processes underlying vascular injury and target-
organ damage in hypertension. Protein phosphatases (protein
tyrosine phosphatases and protein serine/threonine phospha-
tases), which catalyze dephosphorylation of signalling mole-
cules, are highly redox sensitive.43 In the oxidised state,
protein phosphatases are usually inactive, leading to decreased
dephosphorylation of downstream protein targets with
consequent increased phosphorylation and activation, pro-
cesses that are altered in hypertension.44
Hydrogen peroxide is an important diffusible second
messenger that plays a functional role in intercellular signal-
ling through gap junctions, connexins, and myoendothelial
feedback.45,46 H2O2 mediates effects primarily through
oxidation of cysteine thiols. In the endothelium, H2O2 acts as
a vasodilator and has been considered to be an endothelium-
derived relaxing factor, effects that are induced largely through
activation of PKG1a and posttranslational modifications
involving S-glutathionylation.47,48 Increased intracellular
H2O2 promotes phosphorylation of p66Shc, a key mito-
chondrial ROS regulator that involves vascular endothelial
growth factor, which is important in endothelial cell migra-
tion, proliferation, and angiogenesis.49 In vascular smooth
muscle cells, we demonstrated that H2O2 induces post-
translational modification of ERK1/2 and p38MAPK through
tyrosine kinaseedependent, protein kinase C (PKC)einde-
pendent mechanisms, processes that are up-regulated in hy-
pertension.38 Critical to these events is oxidation of protein
tyrosine phosphatases.50 H2O2 has also been implicated in
oxidation of cofilin, an actin-associated protein important in
cell motility migration and vascular remodelling in
hypertension.51Evidence Supporting a Role for ROS and
Oxidative Stress in Hypertension
Oxidative stress has been causally linked to increased blood
pressure in various experimental models of hypertension,
including genetic hypertension (spontaneously hypertensive
rats [SHRs], stroke-prone SHRs [SHR-SPs]), endocrine-
induced hypertension [Ang II, aldosterone, deoxycorticoster-
one acetate (DOCA)]), surgically induced hypertension
(2-kidney 1-clip [2K1C], aortic banding), diet-induced hy-
pertension (salt, fat, zinc), neurogenic hypertension, pulmo-
nary hypertension, and preeclampsia.17,52-56 Biomarkers of
oxidative stress, including plasma and urinary thiobarbituric
acidereactive substances (TBARS) and F2a-isoprostanes, tis-
sue concentrations of O2
 and H2O2, and activation of Noxs
and xanthine oxidase, are increased, whereas levels of NO andantioxidant enzymes are reduced in experimental
hypertension.52-57 Further supporting a role for oxidative
stress in the pathophysiology of hypertension are studies
demonstrating blood pressureelowering effects of antioxi-
dants, ROS scavengers, and Nox inhibitors. Treatment with
antioxidant vitamins (vitamins C and E), SOD mimetics
(tempol [4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl]), free
radical scavengers (N-acetyl-L-cysteine), tetrahydrobiopterin,
nonspecific Nox inhibitors (apocynin, diphenylene iodinium),
and specific Nox inhibitors (gp91dstat, GKT compounds)
reduce oxidative stress and ameliorate or prevent development
of hypertension and associated target-organ damage.58-61
Although experimental data support an etiologic role for
oxidative stress in the development of hypertension, there is
still no confirmation that oxidative stress is a primary cause of
hypertension in humans. Reasons for this are complex, as we
have previously highlighted,62 and relate in large part to 1)
lack of sensitive and specific assays that can accurately assess
redox state in the clinical setting, 2) paucity of mechanistic
studies in disease-appropriate human tissue, and 3) absence of
pharmacologic agents that specifically target Nox isoforms or
ROS that could be used in patients. Nevertheless, there is
clear evidence that ROS production is increased in patients
with essential hypertension, renovascular hypertension, ma-
lignant hypertension, salt-sensitive hypertension,
cyclosporine-induced hypertension, and preeclampsia.63-65
Population-based observational studies reported an inverse
relationship between plasma antioxidants and blood pressure,
and clinical studies have shown that systolic and diastolic
blood pressures correlate positively with biomarkers of
oxidative stress (plasma TBARS and 8-epi-isoprostanes) and
negatively with antioxidant levels in patients with hyperten-
sion.66,67 Plasma levels of asymmetric dimethylarginine
(endothelial NOS inhibitor) and the lipid peroxidation
product of linoleic acid, 13-hydroxyoctadecadienoic acid, a
marker of ROS production, were inversely correlated with
microvascular endothelial dysfunction and elevated blood
pressure in hypertensive patients.68 Endothelial dysfunction, a
hallmark of vascular injury in hypertension, is associated with
increased vascular ROS production, oxidative stress, and
vascular inflammation in patients with hypertension.69 ROS
production in vascular smooth muscle cells (VSMCs) from
arteries of hypertensive patients demonstrated increased Nox
activity, higher levels of O2
 and H2O2, enhanced Ang IIe
stimulated redox signalling, and inflammatory responses
compared with cells from normotensive counterparts.70 There
is also evidence that disruption in ER function (ER stress)
contributes to oxidative stress through increased O2
 gener-
ation, decreased antioxidants and activation of mitochondrial
oxidases.71,72
Causes of oxidative stress in human hypertension are un-
clear but may relate, in part, to decreased antioxidant capacity
and genetic factors.73,74 Correlation between polymorphisms
in glutathione-S-transferase (an intracellular antioxidant
enzyme) and the risk of essential hypertension has been re-
ported.74 Polymorphisms have also been shown in Nox sub-
units in hypertensive patients.75 Individuals with p22phox
polymorphisms exhibit altered Nox activity and increased
ROS production in human cardiovascular disease.76 More
recently, genome-wide association study data from more than
450,000 individuals identified Nox4 and Nox5 as novel blood
Figure 1. Oxidative stress as a unifying factor in hypertension. Prohypertensive factors, eg, angiotensin II (Ang II), endothelin-1 (ET-1), aldosterone
(Aldo), and salt (Na), induce activation of NADPH oxidases (Noxs) that generate reactive oxygen species (ROS), which influence multiple systems
involved in the pathophysiology of hypertension. AT1R, angiotensin II type 1 receptor, ER, endoplasmic reticulum, ETAR, endothelin-1 type A re-
ceptor; MR, mineralocorticoid receptor; TNF, tumour necrosis factor; TNFR, tumour necrosis factor receptor.
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Volume 36 2020pressureerelated genes.77 Although oxidative stress is likely
not the sole cause of hypertension, it amplifies blood pressure
elevation in the presence of other prohypertensive factors,
such as Ang II, ET-1, aldosterone, and salt.Oxidative Stress, Sex, and Hypertension
It is well known that premenopausal women are protected
from hypertension relative to age-matched men and that this
protection is lost with menopause.78 Although the biological
basis for these sex-related differences in hypertension remain
unclear, sex hormones, Y chromosome, Ang II, aldosterone,
and sex hormoneerelated signalling play a critical role.79-81 In
addition, growing evidence suggests that oxidative stress may
be important in the sexual dimorphism in hypertension.82
Both clinical and preclinical studies have demonstrated that
biomarkers of oxidative stress are higher in men than in
women.82-84 In nonhuman male animals, blood pressure de-
creases in response to antioxidants such as tempol and apoc-
ynin, whereas female animals are nonresponsive.82,84
Oxidative stress is involved in the development and mainte-
nance of hypertension in male rats but it seems to be
important only in the initial development of hypertension in
female rats.82 In Ang IIeinduced hypertension in mice,
plasma levels of TBARS were increased in male but not in
female mice.84 Moreover, Ang II induced a significant increasein O2
 and H2O2 production in isolated arteries from male
but not female mice.84 These differences have been attributed
to increased activation of Noxs in males and increased anti-
oxidant capacity in females.85,86 It has also been shown that
estradiol reduces expression and activity of Noxs and increases
expression of antioxidant enzymes superoxide dismutase and
glutathione peroxidase.87 Accordingly, the blunted oxidative
stressemediated increase in blood pressure in females may be
due to increased activation of antioxidant systems and down-
regulation of prooxidant systems.85-87 Taken together, the
current data suggest that oxidative stress may be more
important in blood pressure elevation in males than in
females.Oxidative Stress: A Unifying Mechanism in the
Hypertension Mosaic
Because ROS are key players in regulating cardiovascular
function, it is not surprising that abnormal ROS regulation
and oxidative stress play an important role in the patho-
physiology of hypertension. Moreover, because oxidative stress
influences myriad signalling molecules and pathways in mul-
tiple cells, tissues, organs, and systems, it represents a common
molecular mechanism unifying the multifactorial mosaic
(Fig. 1) that underlies hypertension. Here we focus on some
new concepts relating to the central role of oxidative stress in
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growth factors, aldosterone and signalling through mineralo-
corticoid receptors, and inflammation and the immune
system.Vasoactive Factors, Oxidative Stress, and the
Vasculature
Impaired endothelium-dependent vasorelaxation, increased
vasoconstriction, vascular remodelling and inflammation,
reduced distensibility, and increased stiffness are characteristic
features of small and large arteries in hypertension and
constitute the vascular phenotype, or “vasculopathy,” of hy-
pertension.62,88,89 Some of these vascular changes occur with
physiologic aging, but in hypertension and diabetes the pro-
cesses are accelerated, leading to “premature vascular aging,” a
process that is highly redox sensitive.90,91 These phenomena
are dynamic and involve functional (contraction-relaxation)
and structural changes (remodelling) that occur at different
phases during development of hypertension. They are defined
by complex interactions between vascular cells (endothelium,
VSMCs, adventitial fibroblasts) and circulating elements,
including vasoactive agents, (Ang II, ET-1, aldosterone,
dopamine, catecholamines, prostanoids), growth factors
(epidermal growth factor [EGF], insulin-like growth factor 1
[IGF-1], platelet-derived growth factor [PDGF]), sex hor-
mones, microRNAs, exosomes, and endothelial progenitor
cells.92 In addition, risk factors such as salt and fine particulate
matter (air pollutants) can induce vascular dysfunction and
inflammation in hypertension.93,94 Common to many of
these processes is oxidative stress and activation of redox-
sensitive signalling pathways.34,62,90
Ang II and ET-1
Among the many circulating vasoactive factors involved in
the pathophysiology of hypertension, Ang II and ET-1 are
especially important.95,96 They are potent vasoconstrictor,
mitogenic, and proinflammatory peptides that are critically
involved in regulating the cardiovascular system. Activation of
their respective vascular G proteinecoupled receptors results
in Nox activation and increased generation of ROS, which if
uncontrolled leads to oxidative stress and stimulation of
vascular signalling pathways such as MAPK, PKC, phospho-
lipase C, cellular Src, and Rho kinase (Fig. 2). Increased
vascular ROS bioavailability induced by Ang II, ET-1, and
other vasoactive peptides also cause activation of Ca2þ chan-
nels, leading to accumulation of intracellular Ca2þ which in
turn activates Ca2þ-sensitive Nox isoforms in the vasculature,
specifically Nox5, promoting a feedforward system amplifying
oxidative signalling and vascular damage. Many of these sys-
tems are up-regulated in hypertension. We recently identified
transient receptor potential melastatin 2 cation channel as an
important Ca2þ channel that acts as a link between Ca2þ and
redox signalling, a phenomenon that is increased in VSMCs in
hypertension.97 Vascular oxidative stress is also associated with
altered phosphatase activity that further amplifies kinase sig-
nalling and thus contributes to vascular damage in
hypertension.18
In Ang IIeinduced hypertension in mice and rats,
expression of Nox subunits, activity of Noxs, ROS genera-
tion, and oxidation of signalling molecules are increased.18These processes cause oxidative damage of cells and tissues
with consequent endothelial dysfunction, renal injury, and
cardiovascular remodelling, processes that are attenuated by
angiotensin-converting enzyme inhibitors, ROS scavengers,
and Nox inhibitors.98 Moreover, in mice deficient in Nox2
and p47phox, the blood pressureeelevating effect of Ang II
is blunted.99,100 These findings confirm the central role of
ROS in Ang IIemediated vascular dysfunction and
hypertension.
In addition to influencing Ang II vascular effects, ROS are
important mediators of ET-1einduced cardiovascular
dysfunction and hypertension. In mice overexpressing ET-1
in an endothelial-specific manner, blood pressure was
increased in an ET type A receptor (ETAR)edependent
manner.101 This was associated with reduced renal artery flow,
mesenteric small artery stiffening, endothelial dysfunction,
vascular inflammation, and oxidative stress.101 In mice with
pressure overload and left ventricular hypertrophy induced by
transverse aortic coarctation, cardiac and coronary microvas-
cular dysfunction were causally linked to enhanced ET-1e
induced vasoconstriction, Rho kinase activation, and oxidative
stress.102 In sunitinib-induced hypertension, we showed that
endothelial dysfunction and arterial remodelling involved ET-
1/ETARemediated Nox activation and vascular oxidative
stress.103 Although ET-1 influences cardiovascular function
through ROS generation, ROS themselves regulate the
endothelin system. In Fischer 344 rats infused with a super-
oxide dismutase mimetic (AEOL 10150), plasma oxidative
stress markers and levels of ET-1 were reduced in a dose-
dependent manner.104 Clinically, serum ET-1 levels corre-
lated with biomarkers of oxidative stress in patients with
hypertension.105
Growth factors
Many of the cardiovascular effects of Ang II and ET-1 are
amplified by growth factors in hypertension. Growth factors
such as EGF, IGF-1, and PDGF, which signal through their
cognate receptor tyrosine kinases, induce activation of mito-
genic pathways through ROS-dependent events.106-110 These
processes are also stimulated by Ang II and ET-1, which
transactivate growth factor receptors through various mecha-
nisms, including A disintegrin and metalloproteinase 17
(ADAM17)edependent shedding of growth factors, tyrosine
kinase phosphorylation, and ROS107 (Fig. 2). Vascular
smooth muscle cells from SHRs exhibit increased cell prolif-
eration through Ang II/Ang II type 1 receptor (AT1R)e and
ET-1/ETAReinduced transactivation of EGFR.110-112 These
processes involve increased Nox activity, oxidative stress,
activation of cellular Src, and EGFR-mediated activation of
MAPKs.111 Ang II also transactivates the IGF-1 receptor and
PDGF receptor in VSMCs through ROS generation and
activation of PI3K, p38MAPK, and ERK5 pathways, leading
to vascular hypertrophy and fibrosis.107,110,113,114 The cross-
talk between G proteinecoupled receptor and GFR signal-
ling is up-regulated in hypertension and is influenced by ROS
both upstream and downstream of receptor tyrosine kinase
signaling.107 Accordingly, oxidative stress may be a common
mechanism driving the amplified hypertrophic, fibrotic, and
inflammatory responses induced by Ang II, ET-1, and growth
factors in hypertension.115
Figure 2. Transactivation of growth factor receptors (GFRs) by angiotensin II (Ang II) and endothelin-1 (ET-1), through their G proteinecoupled
receptors (GPCRs), stimulate NADPH oxidase (Nox)ederived reactive oxygen species (ROS) production and activation of ROS-signalling path-
ways that influence cardiovascular processes leading to hypertension-associated target-organ damage.
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An important component of the renin-angiotensin system
in blood pressure regulation is Ang II stimulation of adrenal
cortical cells to produce aldosterone, which signals through
renal mineralocorticoid receptors (MRs) to regulate body
electrolyte and fluid homeostasis.116 Aldosterone also signals
through extrarenal MRs that influence vascular tone, adipose
tissue function, cardiac contraction, and cardiovascular
fibrosis.117,118 High levels of aldosterone are associated with
hypertension, obesity, and increased risk of cardiovascular and
cardiometabolic disease.119,120 Primary hyperaldosteronism
accounts for 5%-15% of patients with hypertension.121
Experimental models of MR-dependent hypertension (deox-
ycorticosterone acetate/salt and aldosterone/salt rodents)
exhibit oxidative stress as evidenced by increased Nox
expression/activity, increased vascular ROS production, and
elevated levels of TBARS, effects that are ameliorated by
treatment with MR antagonists.122-125
Aldosterone signals through its MRs through genomic and
nongenomic pathways, with increasing evidence indicating a
critical role for ROS in these processes. It increases ROS
production in cultured VSMCs126,127 and endothelial cells.128
In VSMCs, aldosterone increases O2
 production primarily
through up-regulation of Nox1,127,129 whereas in endothelial
cells Nox4 seems to be more important.130 NongenomicNox-induced ROS generation by aldosterone/MR involves
cellular Src and Rac-1, as we demonstrated in VSMCs from
SHRs.131 In addition, there is tight interplay between Ang II
and aldosterone redox signalling. Blockade of MRs inhibits
Ang IIeinduced ROS production in vascular tissue,122 and
AT1R is required for MR-induced endothelial dysfunction,
vascular remodelling, inflammation, and oxidative stress in
hypertension.132 In cardiomyocytes, interactions between
MRs and AT1Rs participate in aldosterone-induced ROS
generation through G proteinecoupled receptor kinase
2eregulated Nox4.133
Aldosterone is a potent profibrotic hormone involved in
cardiac and vascular fibrosis and remodelling in hypertension.
These effects are Nox1-ROS dependent129 and involve non-
genomic and genomic signalling through increased expres-
sion/activity of adhesion molecules (intercellular adhesion
molecule 1 [ICAM-1], vascular cell adhesion molecule 1
[VCAM-1]), osteopontin, plasminogen activator inhibitor 1
(PAI-1), and growth factors. Further supporting a role for
ROS in aldosterone-mediated actions are in vitro studies
showing that MR antagonists decrease expression of Nox
isoforms and subunits and attenuate oxidative stress.134,135
Moreover, in vivo studies showed that antioxidants blunt
blood pressureeelevating effects of aldosterone and, in mice
overexpressing MR, that hypertension is associated with
oxidative stress, effects that are absent when MR is knocked
Touyz et al. 665
Oxidative Stress and Hypertensionout in an endothelial-specific manner.136 In addition,
cardiomyocyte-specific overexpression of human MR induces
severe coronary endothelial dysfunction with decreased NO-
mediated relaxing responses to acetylcholine in coronary ar-
teries (but not in peripheral arteries), effects prevented by MR
antagonists, vitamin E/vitamin C, or a Nox inhibitor.137
Beyond its renal and cardiovascular effects, aldosterone
influences immune cells and adipocytes, which also affect
cardiovascular fibrosis and inflammation in hypertension.
MRs are expressed in macrophages and T cells, where they
function as a transcriptional regulator of cellular phenotype
and function. The relationship between immune cells,
MRs, and oxidative stress in hypertension was clearly
demonstrated in aldosterone/saltetreated mice, which
exhibited increased H2O2 production, up-regulation of
oxidative stresseinducible tyrosine phosphatase and man-
ganese-dependent SOD genes, and increased 3-
nitrotyrosine expression in lymphocytes together with
CD4þ inflammatory cells invading intramural coronary
arteries.138 Some of the proinflammatory cardiovascular
effects of aldosterone have been attributed to activation of
macrophage MRs and adipocyte MRs.139,140 In adipocytes,
aldosterone-induced MR activation causes Nox2 activation,
ROS production, and activation of inflammatory pathways.
In adipocytes, aldosterone/MR stimulates production of
proinflammatory adipokines and ROS, which are especially
important in vascular dysfunction in obesity-associated
hypertension.140
Oxidative stress in different cell types, including
VSMCs, endothelial cells, cardiomyocytes, renal cells, im-
mune cells, and adipocytes emerges as an important player
contributing to aldosterone/MReinduced cardiovascular
dysfunction and damage associated with hyper-
aldosteronism. Accordingly, it may be possible that some of
the vasoprotective and antihypertensive effects of MR an-
tagonists, such as epleronone and spironolactone, may be
mediated, at least in part, by inhibiting aldosterone/MRe
induced oxidative stress.Oxidative Stress and Inflammation in
Hypertension
The importance of inflammation in cardiovascular disease
was first suggested by Ross in the 1990s, who showed that
excessive inflammatory-fibroproliferative responses to various
forms of insult to the endothelium and smooth muscle of the
artery wall are critically involved in atherogenesis.141 There is
now extensive experimental and clinical evidence indicating
that hypertension is associated with inflammation, fibrosis,
and activation of immune cells, processes that are driven in
large part by oxidative stress.142 Tissue expression of adhesion
molecules (VCAM-1, ICAM-1), production of inflammatory
mediators (monocyte chemotactic peptide 1, tumour necrosis
factor, interleukin [IL] 1, IL-6, 1L-17), activation of proin-
flammatory signalling pathways (MAPK, STAT) and tran-
scription factors (NF-kB, AP-1, HIF-1), and circulating levels
of inflammatory biomarkers (C-reactive protein, PAI-1, ILs)
are increased in hypertension.143-146 Although it still remains
unclear whether inflammation is a cause or an effect of hy-
pertension, it is clear that the immune system and ROS are
important players.Immunoinflammation, Oxidative Stress, and
Hypertension
The importance of the immune system in the patho-
physiology of hypertension relates primarily to its effects on
inflammation, which is involved in the initiation, progression,
and exacerbation of cardiovascular tissue damage and
remodelling.147 Once activated, immune cells generate high
levels of ROS through Nox-dependent mechanisms, leading
to cytokine production and infiltration of immune cells into
the vascular wall, kidney, and heart, causing tissue damage in
hypertension.148 The damaging effects of immune cell acti-
vation is the consequence of a shift in balance between
proinflammatory and antiinflammatory cytokines and medi-
ators and involve cells of both the adaptive (CD8þ T cells,
CD4þ T cells [TH1, TH2, TH17, Treg cells), B cells] and
innate immune systems (macrophages, monocytes, microglia,
dendritic cells). As part of the innate immune system,
inflammasomes seem to be especially important in inflam-
mation, with increasing evidence suggesting a role for ROS-
induced regulation of inflammasomes in hypertension149,150
The NLRP3 inflammasome platform may play a key role in
coordinating inflammatory responses in hypertension, espe-
cially in the context of caspase-1e, IL-1be, and IL-18e
mediated reactions. Activation of NLRP3 inflammasome
through redox-dependent processes has been shown in Ang
IIemediated and DOCA/salt hypertension and in pre-
eclampsia, pulmonary hypertension, and hypertension-
associated kidney dysfunction.151-154
The importance of the immune system and oxidative stress
in hypertension has been studied in various immunodeficient
mouse models. The adaptive immune system in the patho-
physiology of hypertension was first demonstrated in Rag1/
mice, which lack B and T lymphocytes.155 In these immu-
nodeficient mice, development of hypertension and genera-
tion of ROS induced by Ang II and DOCA/salt were blunted,
effects that were reversed with adoptive transfer of T but not
with B cells.155 Similar blood pressure responses were
observed in mice deficient in macrophage colonyestimulating
factor (op/op/ mice).156 These mice, which lack macro-
phages, are resistant to Ang IIeinduced hypertension and
have reduced ROS generation and vascular inflammation
compared with macrophage-intact mice. In monocyte-
deficient mice, pressor effects and vascular dysfunction
induced by Ang II infusion were blunted, responses that were
restored with adoptive transfer of wild-type monocytes.157
Together, these studies, among many, clearly indicate an
important role for the adaptive and innate immune systems
and oxidative stress in hypertension. Multiple factors have
been implicated in the activation and regulation of immune
cells in hypertension, including catecholamines, Ang II, salt,
ROS, and neoantigens, as discussed in detail in the current
issue of this journal.Conclusion
There has been enormous progress in the understanding of
cardiovascular, renal, and neural mechanisms involved in the
pathophysiology of hypertension. Over the past decade, many
new systems and factors have been identified as being
important in the development of hypertension and
hypertension-associated target-organ damage, including the
666 Canadian Journal of Cardiology
Volume 36 2020immune system, inflammation, sex hormones, microRNAs,
interstitial sodium, the microbiome, and environmental
stressors. Common to these processes is oxidative stress with
associated abnormal redox status and altered redox signalling.
Here we have provided a unifying paradigm whereby oxidative
stress acts as a common mediator of cell injury and inflam-
mation in multiple systems that influence blood pressure
regulation. Although the exact causes of oxidative stress in
hypertension remain unclear, dysregulation of Noxs in car-
diovascular, renal, immune, and neural cells seems to be
important. The most significant consequence of oxidative
stress is increased posttranslational oxidation of proteins and
perturbed redox-dependent signalling. To fully understand
the functional impact of oxidative stress in health and disease,
it will be essential to know how proteins are differentially
oxidised and activated.158-160 This will demand high-fidelity
redox proteomics, which we believe is the next frontier in
the unravelling of mechanism-specific targets in hypertension.Funding Sources
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